Capricor Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$15.8Mnext fiscal year
FY EPS (est.)
-$2.15next fiscal year
Monitoring Framework
Key Performance Indicators
Deramiocel BLA Regulatory Approval Status QuarterlyTarget: FDA Approval
Cash Runway (Months of Operations) Quarterly1,800.0%Target: Maintain > 12 months
Commercial Manufacturing Capacity (Patients/Year) Annually250.0
Watch Items
- FDA PDUFA Target Action Date for Deramiocel BLATrigger: August 22, 2026Action: Monitor FDA decision, labeling discussions, and potential issuance of a Priority Review Voucher (PRV).
- Nippon Shinyaku / NS Pharma Breach-of-Contract LawsuitTrigger: Court ruling or settlement on U.S. distribution rights rescissionAction: Assess impact on commercial launch timeline, direct distribution capabilities, and potential loss of milestone payments.
- Commercial Launch Readiness and CCO ExecutionTrigger: Post-approval commercial launch execution under Michael MaurerAction: Track market access, specialty pharmacy distribution setup, and patient support services onboarding.
Research as of 20 Jun 2026